Topiramate and Pulmonary Pathology: Important Precautions

Patient Monitoring and Management

The American College of Cardiology recommends measuring serum bicarbonate periodically before and during topiramate treatment in patients with pulmonary pathology to minimize the risk of metabolic acidosis and respiratory complications 1, 2
The American Thoracic Society suggests initiating topiramate with low doses (3.75/23 mg if combined with phentermine) and titrating gradually to reduce the risk of respiratory adverse effects 1
The American Academy of Neurology recommends suspending topiramate immediately by gradual reduction if the patient develops dyspnea or hyperventilation, and implementing active cooling measures if symptoms are moderate to severe 2

The American Gastroenterological Association recommends considering semaglutide 2.4 mg as first-line treatment for obesity in patients with significant pulmonary pathology, due to its lack of effect on carbonic anhydrase 3
The American Diabetes Association suggests liraglutide 3.0 mg as a safe alternative for patients with pulmonary pathology 3
The American Heart Association recommends naltrexone-bupropion ER if there are no contraindications for bupropion 3